Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
James B. Bussel, Carola E. Henriksson, Marit Hellum, Per Morten Sandset, Waleed Ghanima, Hoa Tran, Lamya Garabet
Publikováno v:
Platelets. 31:322-328
Immune thrombocytopenia (ITP) patients have thrombocytopenia and increased bleeding risk, but, conversely, they also have increased thrombotic risk which appears to be exacerbated by thrombopoietin-receptor agonist (TPO-RA)-treatment. Microvesicles (
Publikováno v:
Platelets. 30:599-607
Platelet activation underlies the pathology of an acute myocardial infarction (AMI), and dual antiplatelet therapy (DAPT) is administered post-AMI to limit this activation. Platelets express Toll-like receptors (TLRs) 1, 2, and 4 and become potently
Publikováno v:
Platelets. 29:628-631
Pipercillin-tazobactam is a frequently used antibiotic that has a broad spectrum of antibacterial activity. The development of severe thrombocytopenia following the use of piperacillin-tazobactam is unusual. Several mechanisms have been proposed for
Autor:
Michael Holinstat, Ellen M. Voigt, Reheman Adili, Amber J. Veldman, Katherine Mast, Joshua L. West, Luke J. Hurley, Mark K. Larson, Evan S. Meyer, Jordan L. Bormann, Sidney W. Whiteheart, Kaitlynn N. Foss
Publikováno v:
Platelets. 30:271-279
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are associated with a variety of cellular alterations that mitigate cardiovascular disease. However, pinpointing the positive therapeutic effects is challenging due to inconsistent clinical trial result
Publikováno v:
Platelets. 28:614-620
Recently published reports have established a heparin-induced thrombocytopenia (HIT)-mimicking thromboembolic disorder without proximate heparin exposure, called spontaneous HIT syndrome. Although the pathophysiology remains unclear, anti-platelet fa
Autor:
Vassiliki Magafa, Iraklis C. Moschonas, Tahsin F. Kellici, Andreas G. Tzakos, Alexandros D. Tselepis, Vassilios Tsikaris, Panagiotis Stathopoulos, Thomas Mavromoustakos
Publikováno v:
Platelets. 28:812-821
Thrombin is the most potent agonist of human platelets and its effects are primarily mediated through the protease-activated receptors (PARs)-1 and -4. Although PAR-1 has higher affinity for thrombin than PAR-4, both receptors contribute to thrombin-
Autor:
Diana A. Gorog, Mohamed Farag, David Wellsted, Maria Niespialowska-Steuden, Keith Sullivan, Benjamin Artman, Manivannan Srinivasan, Osita Okafor, Arif Anis Khan
Publikováno v:
Platelets. 27:687-693
Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF). There has been no head-to-head comparison of the effect of these agents on ex vivo thrombotic and thrombolytic status.
Autor:
Kent R. Bailey, John A. Heit, S. Mitchell Harman, Brian D. Lahr, Muthuvel Jayachandran, Virginia M. Miller
Publikováno v:
Platelets
Activated platelets serve as a catalyst for thrombin generation and a source of vasoactive and mitogenic factors affecting vascular remodeling. Oral menopausal hormone treatments (MHT) may carry greater thrombotic risk than transdermal products. This
Publikováno v:
Platelets. 8:175-180
The H(1)-histamine receptor antagonist Dithaden(R) inhibited in a dose-dependent manner, human platelet aggregation in vitro that was induced with stimuli in the following rank order of potency: thrombinA23187adrenalineADP. The aggregation of platele